We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-1.07%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.91B
AUM Growth
-$338M
Cap. Flow
-$18.8M
Cap. Flow %
-0.65%
Top 10 Hldgs %
56.63%
Holding
45
New
6
Increased
11
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$87.5M
2
MRK icon
Merck
MRK
+$79.6M
3
GILD icon
Gilead Sciences
GILD
+$79.2M
4
INCY icon
Incyte
INCY
+$60.7M
5
VTRS icon
Viatris
VTRS
+$53.4M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$113M
2
HCA icon
HCA Healthcare
HCA
+$109M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.9M
4
ALKS icon
Alkermes
ALKS
+$37.5M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.2%
2 Miscellaneous 10.86%
3 Technology 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$671M
$35M 1.2%
3,000,000
-2,500,000
-45% -$30.7M
ALKS icon
27
Alkermes
ALKS
$7.72B
$30.2M 1.04%
1,300,000
-1,425,000
-52% -$37.5M
PTCT icon
28
PTC Therapeutics
PTCT
$5.48B
$29.9M 1.03%
750,000
– –
TEVA icon
29
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$22M 0.76%
2,750,000
-2,250,000
-45% -$20.3M
COLL icon
30
Collegium Pharmaceutical
COLL
$711M
$19.6M 0.67%
1,050,000
-950,000
-48% -$18.5M
ZYME icon
31
Zymeworks
ZYME
$1.86B
$13.1M 0.45%
800,000
+50,000
+7% +$1.04M
INGN icon
32
Inogen
INGN
$138M
$6.8M 0.23%
+200,000
New +$7.27M
TECX
33
Tectonic Therapeutic
TECX
$557M
$6.29M 0.22%
136,111
-125,000
-48% -$7.18M
PBYI icon
34
Puma Biotechnology
PBYI
$477M
$6.23M 0.21%
2,050,000
-1,375,000
-40% -$5.97M
TBPH icon
35
Theravance Biopharma
TBPH
$885M
$5.53M 0.19%
500,000
-2,000,000
-80% -$17.4M
NUVA
36
DELISTED
NuVasive, Inc.
NUVA
$5.25M 0.18%
+100,000
New +$5.44M
GKOS icon
37
Glaukos
GKOS
$10.1B
$3.33M 0.11%
+75,000
New +$3.46M
INNV icon
38
InnovAge Holding
INNV
$1.49B
$1.75M 0.06%
350,000
-650,000
-65% -$4.72M
SDC
39
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$999K 0.03%
+425,000
New +$1.78M
AZN icon
40
CALL
AstraZeneca
AZN
$251B
– –
-750,000
Closed -$90.1M
GILD icon
41
CALL
Gilead Sciences
GILD
$181B
– –
-1,500,000
Closed -$105M
HCA icon
42
HCA Healthcare
HCA
$91.8B
– –
-447,500
Closed -$109M
IRTC icon
43
iRhythm Holdings
IRTC
$3.69B
– –
-475,000
Closed -$27.8M
RETA
44
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-685,000
Closed -$68.9M
RDUS
45
DELISTED
Radius Health, Inc.
RDUS
– –
-1,500,000
Closed -$18.6M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Camber Capital Management held 45 positions worth $2.91B, down 10% from $3.25B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Camber Capital Management's Q4 2021 filing shows 6 new, 11 increased, 15 reduced and 6 closed positions. Its largest new stake was Vertex Pharmaceuticals: 450,000 shares worth $98.8M. The largest sale was Tenet Healthcare, an estimated $113M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Technology.

  • Camber Capital Management's largest Q4 2021 buy was Vertex Pharmaceuticals: 450,000 shares worth $98.8M.
  • Camber Capital Management added most to Merck in Q4 2021, an estimated $79.6M increase.
  • Camber Capital Management's biggest Q4 2021 reduction was Tenet Healthcare, cutting an estimated $113M.
  • Camber Capital Management fully exited HCA Healthcare in Q4 2021, selling an estimated $109M.
  • Camber Capital Management's ten largest holdings make up 57% of its $2.91B portfolio in Q4 2021.
  • Camber Capital Management opened 6 new positions and closed 6 in Q4 2021.
  • Camber Capital Management's portfolio value fell 10% quarter-over-quarter to $2.91B.

Based on Camber Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.